← All organizations

Centocor

For profitContributed to NME

Also known as: Centocor BV | Centocor, Inc. | CENTOCOR INC | Centocor Ortho Biotech, Inc. | Centocor Ortho Biotech Products, L.P. | Centocor Ortho Biotech Services, L.L.C. | Centocor Research & Development, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Jul 1, 2011

Acquired by Johnson and Johnson on Jan 1, 1999

Timeline

1970s

Jan 1, 1979
Centocor— Founded

1990s

Sep 14, 1992
muromonab cd3— NDA Organization
Sep 14, 1992
muromonab cd3— NDA Secondary Org
Aug 24, 1998
infliximab— Marketing Organization
Jan 1, 1999
Johnson and Johnson— Acquired By

2000s

Jan 1, 2008
Ortho Biotech, Inc.— Acquired

2010s

Jun 1, 2010
RespiVert— Acquired

Drugs by trial phase (66 distinct, 203 trials)

Phase 4 (4 own, 3 via acquisition)

Phase 3 (9 own, 5 via acquisition)

Phase 2 (5 own, 22 via acquisition)

Phase 1 (6 own, 6 via acquisition)

Other trials (0 own, 6 via acquisition)

Indications

Studied for

Marketed drugs (4)

Subsidiaries (2 direct, 2 total across the full acquisition tree)

Recent trials (50)

NCT01266811Study directorPhase 3Jul 1, 2011
NCT01266811Lead sponsorPhase 3Jul 1, 2011
NCT01266785CollaboratorN/ADec 1, 2010
NCT01258777Lead sponsorPhase 1Oct 1, 2010
NCT01258777Study directorPhase 1Oct 1, 2010
NCT01248793Study directorPhase 3Oct 1, 2010
NCT01248793Lead sponsorPhase 3Oct 1, 2010
NCT01288157Lead sponsorPhase 1Sep 1, 2010
NCT01288157Study directorPhase 1Sep 1, 2010
NCT01248780Study directorPhase 3Sep 1, 2010
NCT01216631CollaboratorPhase 2Sep 1, 2010
NCT01248780Lead sponsorPhase 3Sep 1, 2010
NCT01195207Study directorPhase 1Jun 1, 2010
NCT01195207Lead sponsorPhase 1Jun 1, 2010
NCT01204996Lead sponsorPhase 1May 1, 2010

Details

Founded: Philadelphia, PA, US Jan 1, 1979
First NDA: Sep 14, 1992
Last known activity: Jul 1, 2011